8626531

3 known cases. View patent page →

Cases
3
Active
0
3 closed
Filed
2017–2018
Top venue
D N J
2 cases

Filing activity

2017: 1 case'172018: 2 cases2'18
Cases asserting US Patent 8626531 filed per year.

Celgene Corp. v. Dr. Reddy's Laboratories, Ltd. et al.

settled
Docket:
2:18-cv-06378
Court:
D.N.J.
Filed:
2018-04-12
Terminated:
2020-09-17

Celgene sued Dr. Reddy's Laboratories over generic lenalidomide; the asserted patents included the '784 patent along with 6,315,720, 6,561,977, and 8,626,531. The case settled in 2020, with DRL licensed to sell volume-limited generic lenalidomide after March 2022 and unlimited from no earlier than January 31, 2026.

Celgene Corp. v. Lotus Pharmaceutical Co., Ltd. et al.

settled/consent judgment
Docket:
2:17-cv-06842
Filed:
2017-09-06
Terminated:
2019-09-05

Celgene sued Lotus and Alvogen in D.N.J. asserting a portfolio including US 8,626,531. The court bifurcated and stayed claims as to several patents, and a consent judgment/injunction was entered; the case terminated Sept. 5, 2019.